HIV-associated progressive multifocal leukoencephalopathy: current perspectives

References

• Berger JR. Progressive multifocal leukoencephalopathy and newer biological agents. Drug Saf. 2010;33(11):969–983.
   PubMed Web of Science ®Google Scholar
• White MK, Khalili K. Pathogenesis of progressive multifocal leukoencephalopathy--revisited. J Infect Dis. 2011;203(5):578–586.
   PubMed Web of Science ®Google Scholar
• Major EO. Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med. 2010;61:35–47.
   PubMed Web of Science ®Google Scholar
• Astrom KE, Mancall EL, Richardson EP Jr. Progressive multifocal leuko-encephalopathy: a hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin’s disease. Brain. 1958;81(1):93–111.
   PubMed Web of Science ®Google Scholar
• Zurhein G, Chou SM. Particles resembling papova viruses in human cerebral demyelinating disease. Science. 1965;148(3676):1477–1479.
   PubMed Web of Science ®Google Scholar
• Padgett BL, Walker DL, ZuRhein GM, Eckroade RJ, Dessel BH. Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy. Lancet. 1971;1(7712):1257–1260.
   PubMed Web of Science ®Google Scholar
• Pavlovic D, Patera AC, Nyberg F, Gerber M, Liu M; Progressive Multifocal Leukeoncephalopathy Consortium. Progressive multifocal leukoencephalopathy: current treatment options and future perspectives. Ther Adv Neurol Disord. 2015;8(6):255–273.
   PubMed Web of Science ®Google Scholar
• Brooks BR, Walker DL. Progressive multifocal leukoencephalopathy. Neurol Clin. 1984;2(2):299–313.
   PubMed Web of Science ®Google Scholar
• Berger JR. Progressive multifocal leukoencephalopathy in acquired immunodeficiency syndrome: explaining the high incidence and disproportionate frequency of the illness relative to other immunosuppressive conditions. J Neurovirol. 2003;9(Suppl 1):38–41.
   Google Scholar
• Berger JR, Major EO. Progressive multifocal leukoencephalopathy. Semin Neurol. 1999;19(2):193–200.
   PubMed Web of Science ®Google Scholar
• Berger JR, Pall L, Lanska D, Whiteman M. Progressive multifocal leukoencephalopathy in patients with HIV infection. J Neurovirol. 1998;4(1):59–68.
   PubMed Web of Science ®Google Scholar
• d’ Arminio Monforte A, Cinque P, Mocroft A, et al. Changing incidence of central nervous system diseases in the EuroSIDA cohort. Ann Neurol. 2004;55(3):320–328.
   Web of Science ®Google Scholar
• Engsig FN, Hansen AB, Omland LH, et al. Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: a nationwide cohort study. J Infect Dis. 2009;199(1):77–83.
   PubMed Web of Science ®Google Scholar
• Khanna N, Elzi L, Mueller NJ, et al. Incidence and outcome of progressive multifocal leukoencephalopathy over 20 years of the Swiss HIV Cohort Study. Clin Infect Dis. 2009;48(10):1459–1566.
   PubMed Web of Science ®Google Scholar
• Antinori A, Cingolani A, Lorenzini P, et al. Clinical epidemiology and survival of progressive multifocal leukoencephalopathy in the era of highly active antiretroviral therapy: data from the Italian Registry Investigative Neuro AIDS (IRINA). J Neurovirol. 2003;9(Suppl 1):47–53.
   PubMedGoogle Scholar
• Haider S, Nafziger D, Gutierrez JA, Brar I, Mateo N, Fogle J. Progressive multifocal leukoencephalopathy and idiopathic CD41 lymphocytopenia: a case report and review of reported cases. Clin Infect Dis. 2000;31(4):E20–22.
   Google Scholar
• Ferenczy MW, Marshall LJ, Nelson CD, et al. Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. Clin Microbiol Rev. 2012;25(3):471–506.
   PubMed Web of Science ®Google Scholar
• Bellizzi A, Anzivino E, Rodio DM, Palamara AT, Nencioni L, Pietropaolo V. New insights on human polyomavirus JC and pathogenesis of progressive multifocal leukoencephalopathy. Clin Dev Immunol. 2013;2013:839719.
   PubMedGoogle Scholar
• Major EO, Amemiya K, Tornatore CS, Houff SA, Berger JR. Pathogenesis and molecular biology of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. Clin Microbiol Rev. 1992;5(1):49–73.
   PubMed Web of Science ®Google Scholar
• Lashgari MS, Tada H, Amini S, Khalili K. Regulation of JCVL promoter function: transactivation of JCVL promoter by JCV and SV40 early proteins. Virology. 1989;170(1):292–295.
   Web of Science ®Google Scholar
• Khalili K, White MK, Sawa H, Nagashima K, Safak M. The agnoprotein of polyomaviruses: a multifunctional auxiliary protein. J Cell Physiol. 2005;204(1):1–7.
   Web of Science ®Google Scholar
• Martin JD, King DM, Slauch JM, Frisque RJ. Differences in regulatory sequences of naturally occurring JC virus variants. J Virol. 1985;53(1):306–311.
   Web of Science ®Google Scholar
• Neu U, Maginnis MS, Palma AS, et al. Structure-function analysis of the human JC polyomavirus establishes the LSTc pentasaccharide as a functional receptor motif. Cell Host Microbe. 2010;8(4):309–319.
   Web of Science ®Google Scholar
• Dugan AS, Gasparovic ML, Atwood WJ. Direct correlation between sialic acid binding and infection of cells by two human polyomaviruses (JC virus and BK virus). J Virol. 2008;82(5):2560–2564.
   Web of Science ®Google Scholar
• Neu U, Stehle T, Atwood WJ. The Polyomaviridae: contributions of virus structure to our understanding of virus receptors and infectious entry. Virology. 2009;384(2):389–399.
   PubMed Web of Science ®Google Scholar
• Chapagain ML, Verma S, Mercier F, Yanagihara R, Nerurkar VR. Polyomavirus JC infects human brain microvascular endothelial cells independent of serotonin receptor 2A. Virology. 2007;364(1):55–63.
   PubMed Web of Science ®Google Scholar
• Pho MT, Ashok A, Atwood WJ. JC virus enters human glial cells by clathrin-dependent receptor-mediated endocytosis. J Virol. 2000;74(5):2288–2292.
   PubMed Web of Science ®Google Scholar
• Querbes W, Benmerah A, Tosoni D, Di Fiore PP, Atwood WJ. A JC virus-induced signal is required for infection of glial cells by a clathrin- and eps15-dependent pathway. J Virol. 2004;78(1):250–256.
   Web of Science ®Google Scholar
• Benmerah A, Bayrou M, Cerf-Bensussan N, Dautry-Varsat A. Inhibition of clathrin-coated pit assembly by an Eps15 mutant. J Cell Sci. 1999;112(Pt 9):1303–1311.
   Web of Science ®Google Scholar
• Bantel-Schaal U, Hub B, Kartenbeck J. Endocytosis of adeno-associated virus type 5 leads to accumulation of virus particles in the Golgi compartment. J Virol. 2002;76(5):2340–2349.
   Web of Science ®Google Scholar
• Bousarghin L, Touzé A, Sizaret PY, Coursaget P. Human papillomavirus types 16, 31, and 58 use different endocytosis pathways to enter cells. J Virol. 2003;77(6):3846–3850.
   PubMed Web of Science ®Google Scholar
• Pfeffer S. Membrane domains in the secretory and endocytic pathways. Cell. 2003;112(4):507–517.
   Web of Science ®Google Scholar
• Nielsen E, Severin F, Backer JM, Hyman AA, Zerial M. Rab5 regulates motility of early endosomes on microtubules. Nat Cell Biol. 1999;1(6):376–382.
   Web of Science ®Google Scholar
• Sönnichsen B, De Renzis S, Nielsen E, Rietdorf J, Zerial M. Distinct membrane domains on endosomes in the recycling pathway visualized by multicolor imaging of Rab4, Rab5, and Rab11. J Cell Biol. 2000;149(4):901–914.
   PubMed Web of Science ®Google Scholar
• Merabova N, Kaniowska D, Kaminski R, et al. JC virus agnoprotein inhibits in vitro differentiation of oligodendrocytes and promotes apoptosis. J Virol. 2008;82(3):1558–1569.
   Web of Science ®Google Scholar
• Tretiakova A, Krynska B, Gordon J, Khalili K. Human neurotropic JC virus early protein deregulates glial cell cycle pathway and impairs cell differentiation. J Neurosci Res. 1999;55(5):588–599.
   Web of Science ®Google Scholar
• Gualco E, Urbanska K, Perez-Liz G, et al. IGF-IR-dependent expression of Survivin is required for T-antigen-mediated protection from apoptosis and proliferation of neural progenitors. Cell Death Differ. 2010;17(3):439–451.
   Web of Science ®Google Scholar
• Sariyer IK, Merabova N, Patel PK, et al. Bag3-induced autophagy is associated with degradation of JCV oncoprotein, T-Ag. PloS One. 2012;7(9):e45000.
   Web of Science ®Google Scholar
• Beltrami S, Gordon J. Immune surveillance and response to JC virus infection and PML. J Neurovirol. 2014;20(2):137–149.
   Web of Science ®Google Scholar
• Caracciolo V, Reiss K, Khalili K, De Falco G, Giordano A. Role of the interaction between large T antigen and Rb family members in the oncogenicity of JC virus. Oncogene. 2006;25(38):5294–5301.
   PubMed Web of Science ®Google Scholar
• Krynska B, Gordon J, Otte J, et al. Role of cell cycle regulators in tumor formation in transgenic mice expressing the human neurotropic virus, JCV, early protein. J Cell Biochem. 1997;67(2):223–230.
   PubMed Web of Science ®Google Scholar
• Del Valle L, Wang JY, Lassak A, et al. Insulin-like growth factor I receptor signaling system in JC virus T antigen-induced primitive neuroectodermal tumors--medulloblastomas. J Neurovirol. 2002;8(Suppl 2):138–147.
   Google Scholar
• Chun TW, Fauci AS. HIV reservoirs: pathogenesis and obstacles to viral eradication and cure. AIDS. 2012;26(10):1261–1268.
   PubMed Web of Science ®Google Scholar
• Wortman MJ, Krachmarov CP, Kim JH, et al. Interaction of HIV-1 Tat with Puralpha in nuclei of human glial cells: characterization of RNA-mediated protein-protein binding. J Cell Biochem. 2000;77(1):65–74.
   PubMed Web of Science ®Google Scholar
• Berkhout B, Silverman RH, Jeang KT. Tat trans-activates the human immunodeficiency virus through a nascent RNA target. Cell. 1989;59(2):273–282.
   Web of Science ®Google Scholar
• Berkhout B, Gatignol A, Rabson AB, Jeang KT. TAR-independent activation of the HIV-1 LTR: evidence that tat requires specific regions of the promoter. Cell. 1990;62(4):757–767.
   Web of Science ®Google Scholar
• Berkhout B, Jeang KT. Functional roles for the TATA promoter and enhancers in basal and Tat-induced expression of the human immunodeficiency virus type 1 long terminal repeat. J Virol. 1992;66(1):139–149.
   Web of Science ®Google Scholar
• Chepenik LG, Tretiakova AP, Krachmarov CP, Johnson EM, Khalili K. The single-stranded DNA binding protein, Pur-alpha, binds HIV-1 TAR RNA and activates HIV-1 transcription. Gene. 1998;210(1):37–44.
   Web of Science ®Google Scholar
• Daniel DC, Wortman MJ, Schiller RJ, et al. Coordinate effects of human immunodeficiency virus type 1 protein Tat and cellular protein Puralpha on DNA replication initiated at the JC virus origin. J Gen Virol. 2001;82(Pt 7):1543–1553.
   Google Scholar
• Wright CA, Nance JA, Johnson EM. Effects of Tat proteins and Tat mutants of different human immunodeficiency virus type 1 clades on glial JC virus early and late gene transcription. J Gen Virol. 2013;94(Pt 3):514–523.
   Google Scholar
• Borie D, Kremer JM. Considerations on the appropriateness of the John Cunningham virus antibody assay use in patients with rheumatoid arthritis. Semin Arthritis Rheum. 2015;45(2):163–166.
   PubMed Web of Science ®Google Scholar
• Durali D, de Goër de Herve MG, Gasnault J, Taoufik Y. B cells and progressive multifocal leukoencephalopathy: search for the missing link. Front Immunol. 2015;6:241.
   PubMed Web of Science ®Google Scholar
• Monaco MC, Jensen PN, Hou J, Durham LC, Major EO. Detection of JC virus DNA in human tonsil tissue: evidence for site of initial viral infection. J Virol. 1998;72(12):9918–9923.
   Web of Science ®Google Scholar
• Kato A, Kitamura T, Takasaka T, et al. Detection of the archetypal regulatory region of JC virus from the tonsil tissue of patients with tonsillitis and tonsilar hypertrophy. J Neurovirol. 2004;10(4):244–249.
   Web of Science ®Google Scholar
• Houff SA, Major EO, Katz DA, et al. Involvement of JC virus-infected mononuclear cells from the bone marrow and spleen in the pathogenesis of progressive multifocal leukoencephalopathy. N Engl J Med. 1988;318(5):301–305.
   PubMed Web of Science ®Google Scholar
• Tan CS, Dezube BJ, Bhargava P, et al. Detection of JC virus DNA and proteins in the bone marrow of HIV-positive and HIV-negative patients: implications for viral latency and neurotropic transformation. J Infect Dis. 2009;199(6):881–888.
   Web of Science ®Google Scholar
• Tan CS, Broge TA Jr, Ngo L, et al. Immune reconstitution after allogeneic hematopoietic stem cell transplantation is associated with selective control of JC virus reactivation. Biol Blood Marrow Transplant. 2014;20(7):992–999.
   PubMed Web of Science ®Google Scholar
• Cinque P, Koralnik IJ, Gerevini S, Miro JM, Price RW. Progressive multifocal leukoencephalopathy complicating HIV-1 infection. Lancet Infect Dis. 2009;9(10):625–636.
   PubMed Web of Science ®Google Scholar
• Berger JR, Aksamit AJ, Clifford DB, et al. PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section. Neurology. 2013;80(15):1430–1438.
   PubMed Web of Science ®Google Scholar
• Post MJ, Thurnher MM, Clifford DB, et al. CNS-immune reconstitution inflammatory syndrome in the setting of HIV infection, part 1: overview and discussion of progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome and cryptococcal-immune reconstitution inflammatory syndrome. AJNR Am J Neuroradiol. 2013;34(7):1297–1307.
   PubMed Web of Science ®Google Scholar
• Mikita K, Maeda T, Fujikura Y, et al. Does anti-JCV therapy improve the prognosis of AIDS-related PML? Clin Neurol Neurosurg. 2013;115(9):1853–1854.
   Web of Science ®Google Scholar
• Fanjul F, Riveiro-Barciela M, Gonzalez J, et al. Evaluation of progressive multifocal leukoencephalopathy treatments in a Spanish cohort of HIV-infected patients: do protease inhibitors improve survival regardless of central nervous system penetration-effectiveness (CPE) score? HIV Med. 2013;14(5):321–325.
   PubMed Web of Science ®Google Scholar
• Sidhu N, McCutchan JA. Unmasking of PML by HAART: unusual clinical features and the role of IRIS. J Neuroimmunol. 2010;219(1-2):100–104.
   Web of Science ®Google Scholar
• Shelburne SA 3rd, Hamill RJ. The immune reconstitution inflammatory syndrome. AIDS Rev. 2003;5(2):67–79.
   PubMedGoogle Scholar
• Martin-Blondel G, Bauer J, Cuvinciuc V, et al. In situ evidence of JC virus control by CD8+ T cells in PML-IRIS during HIV infection. Neurology. 2013;81(11):964–970.
   Web of Science ®Google Scholar
• Tan K, Roda R, Ostrow L, McArthur J, Nath A. PML-IRIS in patients with HIV infection: clinical manifestations and treatment with steroids. Neurology. 2009;72(17):1458–1464.
   PubMed Web of Science ®Google Scholar
• Delbue S, Elia F, Carloni C, et al. JC virus load in cerebrospinal fluid and transcriptional control region rearrangements may predict the clinical course of progressive multifocal leukoencephalopathy. J Cell Physiol. 2012;227(10):3511–3517.
   Web of Science ®Google Scholar
• Viscidi RP, Khanna N, Tan CS, et al. JC virus antibody and viremia as predictors of progressive multifocal leukoencephalopathy in human immunodeficiency virus-1-infected individuals. Clin Infect Dis. 2011;53(7):711–715.
   Web of Science ®Google Scholar
• Van Loy T, Thys K, Ryschkewitsch C, et al. JC virus quasispecies analysis reveals a complex viral population underlying progressive multifocal leukoencephalopathy and supports viral dissemination via the hematogenous route. J Virol. 2015;89(2):1340–1347.
   PubMed Web of Science ®Google Scholar
• Van Loy T, Thys K, Tritsmans L, Stuyver LJ. Quasispecies analysis of JC virus DNA present in urine of healthy subjects. PloS One. 2013;8(8):e70950.
   PubMed Web of Science ®Google Scholar
• Berger JR, Houff SA, Gurwell J, Vega N, Miller CS, Danaher RJ. JC virus antibody status underestimates infection rates. Ann Neurol. 2013;74(1):84–90.
   PubMed Web of Science ®Google Scholar
• Laroni A, Giacomazzi CG, Grimaldi L, et al. Urinary JCV-DNA testing during natalizumab treatment may increase accuracy of PML risk stratification. J Neuroimmune Pharmacol. 2012;7(3):665–672.
   Web of Science ®Google Scholar
• Kling CL, Wright AT, Katz SE, et al. Dynamics of urinary polyomavirus shedding in healthy adult women. J Med Virol. 2012;84(9):1459–1463.
   Web of Science ®Google Scholar
• Behzad-Behbahani A, Klapper PE, Vallely PJ, Cleator GM, Khoo SH. Detection of BK virus and JC virus DNA in urine samples from immunocompromised (HIV-infected) and immunocompetent (HIV-non-infected) patients using polymerase chain reaction and microplate hybridisation. J Clin Virol. 2004;29(4):224–229.
   Web of Science ®Google Scholar
• Pietilä T, Nummi M, Auvinen P, Mannonen L, Auvinen E. Expression of BKV and JCV encoded microRNA in human cerebrospinal fluid, plasma and urine. J Clin Virol. 2015;65:1–5.
   PubMed Web of Science ®Google Scholar
• Lagatie O, Van Loy T, Tritsmans L, Stuyver LJ. Circulating human microRNAs are not linked to JC polyomavirus serology or urinary viral load in healthy subjects. Virology Journal. 2014;11:41.
   PubMed Web of Science ®Google Scholar
• Sahraian MA, Radue EW, Eshaghi A, Besliu S, Minagar A. Progressive multifocal leukoencephalopathy: a review of the neuroimaging features and differential diagnosis. Eur J Neurol. 2012;19(8):1060–1069.
   Web of Science ®Google Scholar
• Chapagain ML, Sumibcay L, Gurjav U, Kaufusi PH, Kast RE, Nerurkar VR. Serotonin receptor 2A blocker (risperidone) has no effect on human polyomavirus JC infection of primary human fetal glial cells. J Neurovirol. 2008;14(5):448-454.
   Google Scholar
• Sharma BN, Marschall M, Rinaldo CH. Antiviral effects of artesunate on JC polyomavirus replication in COS-7 cells. Antimicrob Agents Chemother. 2014;58(11):6724–6734.
   Web of Science ®Google Scholar
• Iannetta M, Bellizzi A, Lo Menzo S, et al. HIV-associated progressive multifocal leukoencephalopathy: longitudinal study of JC virus non-coding control region rearrangements and host immunity. J Neurovirol. 2013;19(3):274–279.
   Web of Science ®Google Scholar
• Moenster RP, Jett RA. Mirtazapine and mefloquine therapy for progressive multifocal leukoencephalopathy in a patient infected with human immunodeficiency virus. Am J Health Syst Pharm. 2012;69(6):496–498.
   Web of Science ®Google Scholar
• Cettomai D, McArthur JC. Mirtazapine use in human immunodeficiency virus-infected patients with progressive multifocal leukoencephalopathy. Arch Neurol. 2009;66(2):255–258.
   PubMed Web of Science ®Google Scholar
• Beppu M, Kawamoto M, Nukuzuma S, Kohara N. Mefloquine improved progressive multifocal leukoencephalopathy in a patient with systemic lupus erythematosus. Intern Med. 2012;51(10):1245–1247.
   PubMed Web of Science ®Google Scholar
• Adachi E, Koibuchi T, Imai K, et al. Favourable outcome of progressive multifocal leukoencephalopathy with mefloquine treatment in combination with antiretroviral therapy in an HIV-infected patient. Int J STD AIDS. 2012;23(8):603–605.
   Web of Science ®Google Scholar
• Clifford DB, Nath A, Cinque P, et al. A study of mefloquine treatment for progressive multifocal leukoencephalopathy: results and exploration of predictors of PML outcomes. J Neurovirol. 2013;19(4):351–358.
   PubMed Web of Science ®Google Scholar
• Middel A, Arends JE, van Lelyveld SF, et al. Clinical and immunologic effects of maraviroc in progressive multifocal leukoencephalopathy. Neurology. 2015;85(1):104-106.
   Web of Science ®Google Scholar
• Dang X, Chalkias S, Koralnik IJ. JC virus-iLOV fluorescent strains enable the detection of early and late viral protein expression. J Virol Methods. 2015;223:25–29.
   PubMed Web of Science ®Google Scholar
• Loignon M, Toma E. Treatment options for progressive multifocal leukoencephalopathy in HIV-infected persons: current status and future directions. Expert Rev Anti Infect Ther. 2016;14(2):177–191.
   PubMed Web of Science ®Google Scholar
• Wollebo HS, Woldemichaele B, Khalili K, Safak M, White MK. Epigenetic regulation of polyomavirus JC. Virol J. 2013;10:264.
   PubMed Web of Science ®Google Scholar